ANCA. After the induction treatment, disease was resistant to therapy in 24 (25%) of the patients. Six of the 24 patients (18%) progressed to ESKD over 10.9 m. A response to initial treatment occurred in 74 patients (75%), remission was achieved in 41 patients (55%), while 33 (45%) experienced a relapse. Nine of the 33 patients (38%) progressed to ESKD over 29.2 m. Female sex was a statistically significant predicor of treatment resistance (OR 2.85 [95%CI 1.06-2.86], P = 0.036). Besides, elevated serum creatinine level, with each increment of 150 m mol/L predicted to treatment resistance (P = 0.002). Among the remission patients, those with PR3 ANCA were 1.31 times more likely to experience a relapse than patients with MPO ANCA (95%CI 1.01-5.35) (P = 0.0001). Lung involvement was associated with an increased risk of relapse , P = 0.014). The impact of female sex approached significance .87], P = 0.08). Our findings highlight the important impact of old age, severity of renal disease at presentation as predictors of treatment resistance, and PR3-ANCA, lung involvement as predictors of relapse.
Introduction.-Rituximab is effective in inducing remission in ANCAassociated vasculitis (AAV), with randomised evidence to support its use as four infusions of 375 mg/m 2 (the conventional lymphoma dosing schedule) [1, 2] . As B-cell depletion (BCD) appears to occur very rapidly after the first dose, we questioned the need for repeat dosing and adopted a standard single-dose protocol of 375 mg/m 2 to treat active AAV.
Methods.-All consecutive cases with newly diagnosed or relapsing AAV for whom conventional immunosuppression was contraindicated or ineffective were enrolled. All were Rituximab naïve and 7 (37%) were on additional immunosuppression at the time of Rituximab treatment. Circulating CD19 B-cells and clinical and serological markers of disease activity were recorded at regular intervals. Complete remission (CR) was defined as absence of clinical features of AAV with prednisolone dose < 10 mg/day. Results.-Nineteen patients were included, 17 (89%) with generalised disease and 2 (11%) with severe disease (creatinine level > 500 mM). All but 1 (5%) patient achieved satisfactory BCD (< 0.005 cells/uL) after a median of 13 days. 3-month BCD probability was 92% (Supplementary data). Median time to CR following a single dose of Rituximab was 38 days and the three-month probability of CR was 80%. Median time to B-cell repopulation was 9.5 months, and to disease relapse/re-dose was 27 months. Use of this single-dose protocol saved an estimated £ 4500/patient compared to a 4 Â 375 mg/m 2 dosing schedule.
Conclusion.-Our single centre experience suggests that a single dose of Rituximab of 375 mg/m 2 is a reasonable, and more cost effective, therapy for inducing remission in patients with AAV.
Supplementary data associated with this article can be found on the website of La Pre sse Mé dica le ( h t t p : / / w w w. e mconsulte.com/revue/lpm).
